Enter at least 3 characters
HOME > Press

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Accept this law
PRESS RELEASE
Chiesi, accompagné par IBM, lance WeStart, son premier programme d’innovation ouverte fondé sur le partage et la collaboration.
Chiesi outlines €350 million investment and announces the development of the first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD
Le groupe Chiesi reçoit le prix Diversity Leaders Award 2020
Chiesi investit à nouveau en France!
Chiesi est le plus grand groupe pharmaceutique à obtenir la certification B corp !
COPD, a disease still underestimated by Europeans
Le Groupe Chiesi est l'une des 8 entreprises italiennes invitées par Le Président Français Mr Emmanuel Macron, au Sommet International Français de Versailles « Choose France »
Trimbow® , the first triple combination in a single inhaler for the treatment of COPD -positive opinion from the CHMP in Europe
CHIESI FRANCE INAUGURATES HIS NEW OFFICES AT BOIS-COLOMBES
Publication of Chiesi's TRINITY study in the pages of The Lancet
Chiesi France executive committee evolution
Chiesi France moving Forward
Appointment of Patrice Carayon